Harrow (NASDAQ:HROW) Director Adrienne Graves Buys 1,000 Shares of Stock

Harrow, Inc. (NASDAQ:HROW) Director Adrienne Graves acquired 1,000 shares of Harrow stock in a transaction on Monday, May 18th. The shares were bought at an average price of $31.07 per share, for a total transaction of $31,070.00. Following the purchase, the director owned 1,000 shares of the company’s stock, valued at $31,070. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Harrow Price Performance

HROW stock opened at $30.68 on Wednesday. The firm has a market cap of $1.14 billion, a P/E ratio of -74.83 and a beta of 0.34. The company has a debt-to-equity ratio of 10.30, a quick ratio of 2.30 and a current ratio of 2.48. Harrow, Inc. has a 1 year low of $25.21 and a 1 year high of $54.85. The stock has a 50-day simple moving average of $36.30 and a 200-day simple moving average of $42.07.

Harrow (NASDAQ:HROW) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.31). Harrow had a positive return on equity of 19.59% and a negative net margin of 5.57%.The company had revenue of $44.20 million for the quarter, compared to analyst estimates of $52.43 million. During the same period last year, the firm posted ($0.38) earnings per share. On average, equities analysts predict that Harrow, Inc. will post 0.29 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Harrow

Institutional investors have recently modified their holdings of the stock. University of Texas Texas AM Investment Management Co. acquired a new position in Harrow in the fourth quarter worth about $26,000. KBC Group NV bought a new position in Harrow during the 1st quarter worth approximately $31,000. SBI Securities Co. Ltd. grew its position in shares of Harrow by 393.5% in the 4th quarter. SBI Securities Co. Ltd. now owns 1,061 shares of the company’s stock worth $52,000 after acquiring an additional 846 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Harrow in the 2nd quarter worth approximately $48,000. Finally, State of Alaska Department of Revenue bought a new stake in shares of Harrow in the 3rd quarter valued at approximately $83,000. Institutional investors and hedge funds own 72.76% of the company’s stock.

More Harrow News

Here are the key news stories impacting Harrow this week:

• Positive Sentiment: Director Adrienne L. Graves bought 1,000 shares of Harrow at $31.07 per share, a small but notable insider purchase that can signal confidence in the company’s outlook. SEC filing
• Positive Sentiment: HC Wainwright reiterated a Buy rating and $70 price target on Harrow, implying meaningful upside from current levels.
• Positive Sentiment: The firm raised its Q4 2026 EPS estimate to $0.61 from $0.40, suggesting stronger profitability later in the fiscal year.
• Positive Sentiment: HC Wainwright also sees a stronger back half of the forecast period, including $0.40 EPS in Q3 2027, $1.06 in Q4 2027, and $1.14 for FY2027.
• Neutral Sentiment: At the same time, HC Wainwright cut its FY2026 EPS estimate to $0.15 from $0.56 and reduced Q2 2026 EPS to $0.01 from $0.10, reflecting near-term earnings pressure.
• Neutral Sentiment: The company recently reported a quarterly EPS miss and revenue below expectations, which remains a reminder that execution has been uneven.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on HROW shares. Zacks Research raised shares of Harrow from a “strong sell” rating to a “hold” rating in a research note on Friday, April 3rd. Nomura cut shares of Harrow to a “neutral” rating in a research report on Wednesday, March 18th. BTIG Research restated a “buy” rating and set a $63.00 target price on shares of Harrow in a research note on Tuesday, May 12th. HC Wainwright reiterated a “buy” rating and issued a $70.00 price target on shares of Harrow in a research note on Thursday, March 19th. Finally, Wall Street Zen cut Harrow from a “hold” rating to a “sell” rating in a research note on Saturday. Eight investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Harrow has an average rating of “Moderate Buy” and a consensus target price of $69.43.

Harrow Company Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.